Terumo (4543) Q1 2027 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2027 earnings summary
26 Aug, 2026Executive summary
Achieved record-high quarterly revenue of JPY 311.8 billion, up 19.9% year-on-year, driven by strong global demand, favorable FX, and robust sales in the Americas.
Profitability surged due to robust business performance, a U.S. tariff refund of JPY 13 billion, and JPY 20 billion in one-time settlement proceeds.
Operating profit and adjusted operating profit reached new highs, supported by one-time income and settlement proceeds.
Full-year profit guidance revised upward to reflect these one-time gains, while revenue outlook remains unchanged.
Comprehensive income soared to JPY 99.6 billion, mainly due to FX translation gains.
Financial highlights
Revenue increased 19.9% year-on-year to JPY 311.8 billion, with 9% growth on a local currency basis.
Operating profit rose 60% year-on-year to JPY 89.5 billion; adjusted operating profit up 34.7% to JPY 79.6 billion.
Gross margin improved to 57.3% from 56.0% year-on-year, benefiting from pricing measures and FX effects.
Profit for the period surged 68% year-on-year to JPY 70.4 billion.
Free cash flow rose 331% year-on-year to JPY 46.2 billion.
Outlook and guidance
Full-year revenue outlook maintained at JPY 1.239 trillion (+9.5% YoY).
Adjusted operating profit guidance raised to JPY 274.5 billion (22.2% margin); OP margin expected at 20.8%.
Profit attributable to owners forecast at JPY 193.1 billion (+42.1% YoY); EPS guidance at JPY 130.91.
Record highs in both revenue and profit expected for FY 2026.
Upward revision reflects U.S. tariff refund and settlement proceeds.
Latest events from Terumo
- FY26 targets robust growth through innovation, new devices, and expansion in Africa and organ technologies.4543
Investor Day 2026 - Record revenue and profit, with double-digit growth expected to continue in FY2026/2027.4543
Q4 2026 - Record revenue and profit growth driven by global demand and strategic acquisitions.4543
Q3 2026 - Innovation, M&A, and new launches fuel global growth and margin expansion.4543
44th Annual J.P. Morgan Healthcare Conference - $1.5B acquisition accelerates entry into organ transplantation, driving growth and innovation.4543
M&A Announcement - Record sales and profit surge drive raised guidance, innovation, and share split.4543
Q2 2025 - Record revenue and profit growth, with double-digit gains and improved margins.4543
Q1 2025 - Record revenue and profit growth, with global expansion and CDMO investment; tariff risks persist.4543
Q4 2025 - Record revenue and profit growth driven by global demand, pricing, and FX gains.4543
Q3 2025